SEDAR-SEMICYUC共识建议:重症COVID-19感染患者止血紊乱的管理
SARS-CoV-2感染主要引起呼吸系统病变,重症患者常进展为急性呼吸窘迫综合征,可能 predispose 至高凝状态,伴静脉和动脉血栓形成。其病理生理为多因素,与缺氧及严重炎症过程相关,并包括许多患者存在的额外血栓形成因素。为优化高凝状态管理,SEDAR与SEMICYUC工作组制定共识,针对重症COVID-19患者止血紊乱提出行动指南。推荐涵盖静脉血栓栓塞预防、围产期管理、长期抗血小板或抗凝治疗患者的管理、病程中出血并发症及一般止血指标解读。
要点
- 重症COVID-19患者常进展为ARDS,可能 predispose 至高凝状态,伴静脉和动脉血栓形成。
- 高凝状态病理生理为多因素,与缺氧、严重炎症过程及许多患者存在的额外血栓形成因素相关。
- SEDAR与SEMICYUC共识推荐涵盖静脉血栓栓塞预防、围产期管理、长期抗血小板或抗凝治疗管理、出血并发症及止血指标解读。
适用人群与场景
- 重症COVID-19感染患者。
- 围产期患者。
- 长期接受抗血小板或抗凝治疗的患者。
处置流程与药物剂量
- 推荐包括静脉血栓栓塞疾病的预防。
- 推荐包括围产期的管理。
- 推荐包括长期抗血小板或抗凝治疗患者的管理。
- 推荐包括病程中出血并发症的管理。
- 推荐包括一般止血指标解读。
研究设计与关键结果
- SEDAR与SEMICYUC工作组制定共识,以建立针对重症COVID-19患者止血紊乱的行动指南。
证据类型、等级与局限
- 证据类型:共识推荐。
- 局限:原文未报告局限性
对床旁实践的改变
- 原文未据此给出推荐。
指南或共识出处
- SEDAR-SEMICYUC共识建议:重症COVID-19感染患者止血紊乱的管理,由西班牙麻醉学-复苏与疼痛治疗学会(SEDAR)和重症、危重医学与冠状动脉单元学会(SEMICYUC)制定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID-19, mainly causes alterations in the respiratory system. In severely ill patients, the disease often evolves into an acute respiratory distress syndrome that can predispose patients to a state of hypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatory process linked to this pathology, including the additional thrombotic factors present in many of the patients. In view of the need to optimise the management of hypercoagulability, the working groups of the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observed in severely ill patients with COVID-19. These recommendations include prophylaxis of venous thromboembolic disease in these patients, and in the peripartum, management of patients on long-term antiplatelet or anticoagulant treatment, bleeding complications in the course of the disease, and the interpretation of general alterations in haemostasis.
The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID-19, mainly causes alterations in the respiratory system. In severely ill patients, the disease often evolves into an acute respiratory distress syndrome that can predispose patients to a state of hypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatory process linked to this pathology, including the additional thrombotic factors present in many of the patients. In view of the need to optimise the management of hypercoagulability, the working groups of the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observed in severely ill patients with COVID-19. These recommendations include prophylaxis of venous thromboembolic disease in these patients, and in the peripartum, management of patients on long-term antiplatelet or anticoagulant treatment, bleeding complications in the course of the disease, and the interpretation of general alterations in haemostasis.
参考来源
- Llau JV, Ferrandis R, Sierra P, et al. SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection. Rev Esp Anestesiol Reanim (Engl Ed). 2020. PMID: 32591185. doi:10.1016/j.redar.2020.05.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。